Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
Adenocarcinoma, Clear Cell
/ epidemiology
Adenocarcinoma, Mucinous
/ epidemiology
Adult
Aged
Aged, 80 and over
Ataxia Telangiectasia Mutated Proteins
/ genetics
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Carcinoma, Endometrioid
/ epidemiology
Carcinoma, Ovarian Epithelial
/ epidemiology
Cohort Studies
DNA Mismatch Repair
/ genetics
Female
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Homologous Recombination
Humans
Japan
/ epidemiology
Middle Aged
Ovarian Neoplasms
/ epidemiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 11 2019
28 11 2019
Historique:
received:
28
08
2019
accepted:
04
11
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
20
11
2020
Statut:
epublish
Résumé
We explored the frequency of germline and somatic mutations in homologous recombination (HR)-associated genes in major histological types of ovarian cancer. We performed targeted sequencing to assess germline and somatic mutations of 16 HR-associated genes and 4 mismatch repair (MMR) genes among 207 ovarian cancer patients (50 high-grade serous carcinomas (HGSC), 99 clear cell carcinomas (CCC), 39 endometrioid carcinomas (EC), 13 mucinous carcinomas (MC), and 6 low-grade serous carcinomas (LGSC)). Germline or somatic mutations of HR-associated genes were detected in 44% of HGSC, 28% of CCC, 23% of EC, 16% of MC, and 17% of LGSC patients. The profile of HR-associated gene mutations was remarkably different among each histological type. Germline BRCA1/2 mutations were frequently detected in HGSC and were rarely observed in CCC, EC, and MC patients. ATM somatic mutation was more frequently detected in CCC (9%) and EC patients (18%) than in HGSC patients (4%). There was a positive correlation between MMR gene mutations and HR-associated gene mutations (p = 0.0072). Our findings might be useful in selection of ovarian cancer patients that should be treated with PARP inhibitors.
Identifiants
pubmed: 31780705
doi: 10.1038/s41598-019-54116-y
pii: 10.1038/s41598-019-54116-y
pmc: PMC6882827
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
ATM protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17808Références
Blood. 2010 Nov 25;116(22):4578-87
pubmed: 20739657
J Pathol. 2012 Feb;226(3):413-20
pubmed: 22102435
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Oncotarget. 2017 Jun 20;8(25):40152-40168
pubmed: 27374179
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Br J Cancer. 2018 Nov;119(11):1401-1409
pubmed: 30353044
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Cancer. 2016 Jan 1;122(1):84-90
pubmed: 26439132
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Gynecol Oncol. 2017 Feb;144(2):396-404
pubmed: 27919574
BMC Cancer. 2018 Mar 5;18(1):254
pubmed: 29506471
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049
pubmed: 31263023
Annu Rev Biochem. 2010;79:181-211
pubmed: 20192759
Clin Cancer Res. 2012 Mar 1;18(5):1374-85
pubmed: 22241791
J Hum Genet. 2017 Apr;62(5):561-567
pubmed: 28179634
N Engl J Med. 2010 Oct 14;363(16):1532-43
pubmed: 20942669
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
pubmed: 25355519
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Genome Med. 2015 Aug 07;7(1):87
pubmed: 26257827
J Clin Oncol. 2015 Nov 20;33(33):3858-65
pubmed: 26282658
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
JAMA. 2012 Jan 25;307(4):382-90
pubmed: 22274685
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
JAMA Oncol. 2019 Jun 13;:
pubmed: 31194225
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29795040
Oncotarget. 2017 Nov 28;8(68):112258-112267
pubmed: 29348823
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Elife. 2014 Aug 01;3:e02725
pubmed: 25085081
Int J Mol Sci. 2016 Dec 15;17(12):
pubmed: 27983698
BMC Cancer. 2006 Jul 31;6:201
pubmed: 16879751
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Arch Gynecol Obstet. 2016 Jun;293(6):1367
pubmed: 27075494
Cancer. 2000 Jun 1;88(11):2584-9
pubmed: 10861437
Genes Chromosomes Cancer. 2018 Feb;57(2):51-60
pubmed: 29044863
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Gynecol Oncol. 2018 Jul;150(1):9-13
pubmed: 29739622
Clin Cancer Res. 2018 Sep 15;24(18):4482-4493
pubmed: 29858219
Rev Biol Trop. 2011 Dec;59(4):1743-55
pubmed: 22208090
Transl Oncol. 2017 Apr;10(2):190-196
pubmed: 28182994
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Gynecol Oncol. 2018 Jul;150(1):127-135
pubmed: 29793804
Br J Cancer. 2017 Aug 22;117(5):717-724
pubmed: 28728166
PLoS Genet. 2018 Dec 26;14(12):e1007752
pubmed: 30586411
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110